Nabriva Therapeutics plc [NASDAQ: NBRV] loss -0.77% on the last trading session, reaching $1.29 price per share at the time. The company report on June 8, 2021 that Crestone Joins Antimicrobials Working Group.
The Antimicrobials Working Group (AWG) announced the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 12 antimicrobial drug companies.
Crestone is a clinical stage biopharmaceutical company focused on inventing and developing novel small molecule drugs for serious bacterial infections, including C. difficile Infection (CDI), resistant Gram-positive infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), and chronic infections such as nontuberculous mycobacterial (NTM) disease. Their lead product candidate, CRS3123, for the treatment of CDI, is in Phase 2 clinical development sponsored by NIAID (NIH) and has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the FDA.
Nabriva Therapeutics plc represents 49.41 million in outstanding shares, while the company has a total market value of $64.20 million with the latest information. NBRV stock price has been found in the range of $1.27 to $1.32.
If compared to the average trading volume of 3.85M shares, NBRV reached a trading volume of 839596 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Nabriva Therapeutics plc [NBRV]:
Wedbush have made an estimate for Nabriva Therapeutics plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 19, 2020. The new note on the price target was released on May 02, 2019, representing the official price target for Nabriva Therapeutics plc stock. Previously, the target price had yet another drop from $9 to $7, while H.C. Wainwright kept a Buy rating on NBRV stock.
The Average True Range (ATR) for Nabriva Therapeutics plc is set at 0.08, with the Price to Sales ratio for NBRV stock in the period of the last 12 months amounting to 9.44. The Price to Book ratio for the last quarter was 0.62, with the Price to Cash per share for the same quarter was set at 1.10.
Trading performance analysis for NBRV stock
Nabriva Therapeutics plc [NBRV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.51. With this latest performance, NBRV shares dropped by -5.84% in over the last four-week period, additionally sinking by -46.69% over the last 6 months – not to mention a drop of -80.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBRV stock in for the last two-week period is set at 37.17, with the RSI for the last a single of trading hit 33.46, and the three-weeks RSI is set at 39.02 for Nabriva Therapeutics plc [NBRV]. The present Moving Average for the last 50 days of trading for this stock 1.4552, while it was recorded at 1.3360 for the last single week of trading, and 2.9022 for the last 200 days.
Nabriva Therapeutics plc [NBRV]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Nabriva Therapeutics plc [NBRV] shares currently have an operating margin of -1315.42 and a Gross Margin at +68.45. Nabriva Therapeutics plc’s Net Margin is presently recorded at -1382.22.
Return on Total Capital for NBRV is now -113.39, given the latest momentum, and Return on Invested Capital for the company is -121.27. Return on Equity for this stock declined to -186.76, with Return on Assets sitting at -91.10. When it comes to the capital structure of this company, Nabriva Therapeutics plc [NBRV] has a Total Debt to Total Equity ratio set at 23.32. Additionally, NBRV Total Debt to Total Capital is recorded at 18.91, with Total Debt to Total Assets ending up at 13.22. Long-Term Debt to Equity for the company is recorded at 17.16, with the Long-Term Debt to Total Capital now at 13.92.
Reflecting on the efficiency of the workforce at the company, Nabriva Therapeutics plc [NBRV] managed to generate an average of -$965,056 per employee. Receivables Turnover for the company is 1.51 with a Total Asset Turnover recorded at a value of 0.07.Nabriva Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 4.30.
An analysis of insider ownership at Nabriva Therapeutics plc [NBRV]
There are presently around $4 million, or 8.60% of NBRV stock, in the hands of institutional investors. The top three institutional holders of NBRV stocks are: FMR LLC with ownership of 1,343,459, which is approximately -6.003% of the company’s market cap and around 1.30% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 425,650 shares of the stock with an approximate value of $0.55 million in NBRV stocks shares; and AISLING CAPITAL MANAGEMENT LP, currently with $0.25 million in NBRV stock with ownership of nearly New of the company’s market capitalization.
Positions in Nabriva Therapeutics plc stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 14 institutional holders increased their position in Nabriva Therapeutics plc [NASDAQ:NBRV] by around 734,077 shares. Additionally, 14 investors decreased positions by around 1,017,376 shares, while 9 investors held positions by with 1,309,604 shares. The mentioned changes placed institutional holdings at 3,061,057 shares, according to the latest SEC report filing. NBRV stock had 8 new institutional investments in for a total of 497,225 shares, while 6 institutional investors sold positions of 203,274 shares during the same period.